$3.69 Billion is the total value of Artal Group S.A.'s 152 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 47.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARGX | Sell | ARGENX SEsponsored adr | $175,095,000 | +0.4% | 500,000 | -13.4% | 4.75% | +21.8% |
| ALNY | Sell | ALNYLAM PHARMACEUTICALS INC | $110,227,000 | -16.6% | 650,000 | -7.1% | 2.99% | +1.1% |
| FOLD | Sell | AMICUS THERAPEUTICS INC | $69,300,000 | +8.4% | 6,000,000 | -10.4% | 1.88% | +31.4% |
| C | Sell | CITIGROUP INCcall | $60,390,000 | -57.0% | 1,000,000 | -50.0% | 1.64% | -47.8% |
| CERE | Sell | CEREVEL THERAPEUTICS HLDNG I | $48,630,000 | -8.4% | 1,500,000 | -16.7% | 1.32% | +11.1% |
| CYTK | Sell | CYTOKINETICS INC | $45,580,000 | -1.9% | 1,000,000 | -23.1% | 1.24% | +18.9% |
| PTGX | Sell | PROTAGONIST THERAPEUTICS INC | $42,750,000 | +60.8% | 1,250,000 | -16.7% | 1.16% | +95.0% |
| RUBY | Sell | RUBIUS THERAPEUTICS INC | $35,831,000 | -51.8% | 3,701,580 | -10.9% | 0.97% | -41.5% |
| ITOS | Sell | ITEOS THERAPEUTICS INC | $25,331,000 | -5.6% | 544,047 | -45.3% | 0.69% | +14.3% |
| VRTX | Sell | VERTEX PHARMACEUTICALS INCcall | $21,960,000 | -39.5% | 100,000 | -50.0% | 0.60% | -26.6% |
| TPTX | Sell | TURNING POINT THERAPEUTICS I | $11,925,000 | -48.7% | 250,000 | -28.6% | 0.32% | -37.7% |
| EQT | Exit | EQT CORP | $0 | – | -9,678 | -100.0% | -0.00% | – |
| ATUS | Exit | ALTICE USA INCcl a | $0 | – | -27,000 | -100.0% | -0.01% | – |
| AVTR | Exit | AVANTOR INC | $0 | – | -50,000 | -100.0% | -0.05% | – |
| Exit | OLAPLEX HLDGS INC | $0 | – | -225,000 | -100.0% | -0.12% | – | |
| BPMC | Exit | BLUEPRINT MEDICINES CORP | $0 | – | -100,000 | -100.0% | -0.23% | – |
| DRNA | Exit | DICERNA PHARMACEUTICALS INC | $0 | – | -700,000 | -100.0% | -0.32% | – |
| BABA | Exit | ALIBABA GROUP HLDG LTDsponsored ads | $0 | – | -100,000 | -100.0% | -0.33% | – |
| MRK | Exit | MERCK & CO INCcall | $0 | – | -500,000 | -100.0% | -0.84% | – |
| FCX | Exit | FREEPORT-MCMORAN INCcall | $0 | – | -3,500,000 | -100.0% | -2.55% | – |
| XLRN | Exit | ACCELERON PHARMA INC | $0 | – | -1,000,000 | -100.0% | -3.85% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AGENUS INC | 42 | Q3 2023 | 1.9% |
| IRONWOOD PHARMACEUTICALS INC | 42 | Q3 2023 | 0.3% |
| ALNYLAM PHARMACEUTICALS INC | 37 | Q3 2023 | 5.1% |
| LEXICON PHARMACEUTICALS INC | 34 | Q3 2023 | 20.6% |
| AMICUS THERAPEUTICS INC | 30 | Q3 2023 | 2.7% |
| BEIGENE LTD | 28 | Q3 2023 | 7.4% |
| BK OF AMERICA CORP | 28 | Q1 2021 | 4.3% |
| SAGE THERAPEUTICS INC | 28 | Q2 2023 | 1.9% |
| AGIOS PHARMACEUTICALS INC | 28 | Q2 2020 | 1.1% |
| NEKTAR THERAPEUTICS | 27 | Q2 2020 | 1.3% |
View Artal Group S.A.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| WEIGHT WATCHERS INTERNATIONAL INC | February 13, 2015 | 29,443,300 | 51.9% |
View Artal Group S.A.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-05-17 |
| 4 | 2024-05-14 |
| 13F-HR | 2024-05-13 |
| 4 | 2024-03-25 |
| 4 | 2024-03-13 |
| 4 | 2024-02-29 |
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-13 |
| 4 | 2023-10-16 |
| 13F-HR | 2023-08-11 |
View Artal Group S.A.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.